

### **Amendments to the Claims**

The following listing of claims replaces all prior listings and versions of claims in this application.

Claims 1-9. (Cancelled)

10. (Currently Amended) A pharmaceutical composition comprising as an active ingredient a peptide selected from the group consisting of:

H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Ileu- Ala-OH (SEQ ID NO: 1);  
H-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (SEQ ID NO:2);  
H-Thr-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (SEQ ID NO:4);  
H-Lys-Gly-Asn-Tyr-MeAla-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 5);  
H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:6);  
H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID NO:7);  
H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:8);  
H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 13);  
H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO:10);  
H-Lys-Ala-His-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO:12);  
H-Lys-Ser-Arg-Thr-Thr-Ser-His-Gly-Arg-Val-Gly-OH (SEQ ID NO: 14);  
H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO:11);  
H-Lys-MeGly-Asn-Tyr-MeAla-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:16); and  
their N-methylated analogs, ~~homologs or derivatives~~, together with a pharmaceutically acceptable diluent or excipient.

Claims 11-12. (Cancelled)

13. (Previously Presented) The pharmaceutical composition of claim 10, further comprising at least one protease inhibitor present in an amount sufficient to prevent peptide degradation.

14. (Previously Presented) The pharmaceutical composition of claim 10, further comprising at least one additional anti-inflammatory agent.
15. (Original) The pharmaceutical composition of claim 14, wherein the additional anti-inflammatory agent is a chemokine modulator.
16. (Currently Amended) A method for protecting or treating an individual against ~~noxious stimuli~~ thermal or chemical induced burns ~~or inflammatory processes~~ which comprises administering to an individual in need of such treatment a therapeutically effective amount of the pharmaceutical composition of claim 10.

Claims 17-21. (Cancelled)

22. (Currently Amended) The method of claim 16, wherein the pharmaceutical composition is administered prior to onset of ~~inflammation or exposure to the noxious stimulus~~ thermal or chemical induced burns.
23. (Currently Amended) The method of claim 16, wherein the pharmaceutical composition is administered after onset of ~~inflammation or exposure to the noxious stimulus~~ thermal or chemical induced burns.
24. (Previously Presented) The method of claim 16, wherein the pharmaceutical composition is administered by parenteral injection.
25. (Original) The method of claim 24, wherein the injection is selected from the group consisting of intravenous, intramuscular, intradermal, intralesional, intrathecal and subcutaneous injections.
26. (Currently Amended) The method of claim 16, wherein the pharmaceutical composition is administered via transdermal, oral, rectal, topical, nasal, inhalation ~~[[and]]~~ or ocular modes of treatment.

Claims 27-35. (Cancelled)

36. (Currently Amended) A peptide selected from the group consisting of:  
H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 1);  
H -Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (SEQ ID NO:2);  
H -Thr-Thr-Asp-Thr-Glu-Phe-Glu-Ala-Ala-Gly-Gly-Gly-Val-Arg-OH (SEQ ID NO:4);  
H-Lys-Gly-Asn-Tyr-MeAla-Glu-Arg-Ileu-Ala-OH (SEQ ID NO: 5);  
H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:6);  
H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Ileu-Ala-OH (SEQ ID NO:7);  
H-Lys-MeGly-Asn-Tyr-Ala-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:8);  
H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 13);  
H-Lys-Gly-Asn-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 10);  
H-Lys-Ala-His-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO: 12);  
H-Lys-Ser-Arg-Thr-Thr-Ser-His-Gly-Arg-Val-Gly-OH (SEQ ID NO: 14);  
H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO:11);  
H-Lys-MeGly-Asn-Tyr-MeAla-Glu-Arg-Melleu-Ala-OH (SEQ ID NO:16); and  
[[an]] a methylated analog, homolog, or derivative thereof.

37. (Previously Presented) The peptide according to claim 36 consisting of the amino acid sequence H-Lys-Gly-Asn-Tyr-Ser-Glu-Arg-Val-Gly-OH (SEQ ID NO:11).

38. (Previously Presented) The peptide according to claim 36 consisting of the amino acid sequence H-Lys-Gly-His-Tyr-Ala-Glu-Arg-Val-Gly-OH (SEQ ID NO: 13).

Claims 39-40. (Cancelled)

41. (Currently Amended) A method for treating Parkinson's ~~a degenerative~~ disease in an individual which comprises administering to an individual in need of such treatment a therapeutically effective amount of a peptide ~~according to claim 36~~ selected from the group consisting of SEQ ID NOs:1, 5-8, 10-14 and 16.

42. (Currently Amended) A method for treating Parkinson's a degenerative disease in an individual which comprises administering to an individual in need of such treatment a pharmaceutical composition ~~that includes~~ comprising a therapeutically effective amount of a peptide ~~according to claim 36~~ selected from the group consisting of SEQ ID NOs:1, 5-8, 10-14 and 16, and a pharmaceutically acceptable diluent or excipient.

Claims 43-44. (Cancelled)

45. (New) A method for preventing, treating or managing symptoms in an individual having an inflammatory disease which comprises administering to an individual in need of such treatment a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NOs:1, 5-8, 10-14 and 16.

46. (New) A method for preventing, treating or managing symptoms in an individual having an inflammatory disease which comprises administering to an individual in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NOs:1, 5-8, 10-14 and 16, and a pharmaceutically acceptable diluent or excipient.

47. (New) The method of claim 46, wherein the pharmaceutical composition is administered prior to onset of inflammation.

48. (New) The method of claim 46, wherein the pharmaceutical composition is administered after onset of inflammation.

49. (New) The method of claim 46, wherein the pharmaceutical composition is administered by parenteral injection.

50. (New) The method of claim 49, wherein the injection is selected from the group consisting of intravenous, intramuscular, intradermal, intralesional, intrathecal and subcutaneous injections.

51. (New) The method of claim 46, wherein the pharmaceutical composition is administered via transdermal, oral, rectal, topical, nasal, inhalation or ocular modes of treatment.

52. (New) The method of claim 51, wherein the pharmaceutical composition is administered orally.

53. (New) The method of claim 46, wherein the individual to be treated has a disease or condition selected from the group consisting of psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, inflammatory bowel disease including Crohn's disease, arthritis including rheumatoid arthritis, asthma, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, muscular dystrophy, sepsis and peritonitis.